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As neonatal intensive care has evolved, the focus has shifted from improving mortality
alone to an effort to improve both mortality and morbidity. The most frequent source of
neonatal brain injury occurs as a result of hypoxic-ischemic injury. Hypoxic-ischemic injury
occurs in about 2 of 1,000 full-term infants and severe injured infants will have lifetime
disabilities and neurodevelopmental delays. Most recently, remarkable efforts toward neu-
roprotection have been started with the advent of therapeutic hypothermia and a key step
in the evolution of neonatal neuroprotection is the discovery of biomarkers that enable the
clinician-scientist to screen infants for brain injury, monitor progression of disease, identify
injured brain regions, and assess efficacy of neuroprotective clinical trials. Lastly, biomark-
ers offer great hope identifying when an injury occurred shedding light on the potential
pathophysiology and the most effective therapy. In this article, we will review biomarkers
of HIE including S100B, neuron specific enolase, umbilical cord IL-6, CK-BB, GFAP, myelin
basic protein, UCHL-1, and pNF-H. We hope to contribute to the awareness, validation, and
clinical use of established as well as novel neonatal brain injury biomarkers.
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INTRODUCTION
Biomarkers are molecules released by or specific to a particular
organ, can give a glimpse into the physiologic or pathologic status
of that specific organ (Ling and Sylvester, 2011). Biomarkers can
be obtained from the blood, urine, cerebrospinal fluid (CSF), or
any other bodily fluid. In neonates with brain injury, biomarkers
may be able to predict the degree and location of injury shortly
after the injury occurs. The discovery of neonatal brain injury
biomarkers is a key step in neonatal neuroprotection. Biomarkers
may enable the clinician-scientist to screen infants for brain injury,
monitor the progression of disease, identify injured brain regions,
and assess the efficacy of neuroprotective strategies procedures
in clinical trials. In addition, large-scale validation of the poten-
tial biomarkers is required, because the potential confounders
(especially for biomarkers that are non-organ specific such as
inflammatory mediators). Currently, clinicians do not routinely
use biomarkers to care for neonates with brain injuries. This review
will examine potential biomarkers the bedside clinician-scientist
may use to hone the treatment of neonates with hypoxic-ischemic
encephalopathy.
HYPOXIC-ISCHEMIC ENCEPHALOPATHY
Systemic asphyxia manifests in the brain as hypoxic-ischemic
encephalopathy (HIE; Vannucci, 1997). Systemic asphyxia occurs
Abbreviations: aEEG, amplitude integrated electroencephalogram; BDNF, brain
derived neurotrophic factor; CPK-BB, brain type creatine phosphokinase; CSF,
cerebrospinal fluid; GFAP, glial fibrillary acidic protein; HIE, hypoxic-ischemic
encephalopathy; IL-6, interleukin-6; NSE, neuron specific enolase; UCHL-1,
ubiquitin carboxyl-terminal hydrolase L1.
in about 2% of full-term infants and in nearly 60% of very low
birth weight (premature) newborns (Mulligan et al., 1980; Gif-
fard et al., 1990; Low et al., 1997). Twenty to fifty percent of
asphyxiated babies who exhibit severe HIE die during the new-
born period (MacDonald et al., 1980). Of the survivors of severe
HIE, up to 25% have permanent neuropsychological handicaps
in the form of learning disabilities, epilepsy, cerebral palsy, with
or without associated mental retardation, learning disabilities,
or epilepsy (Finer et al., 1981; Robertson et al., 1989). Systemic
asphyxia that causes HIE may occur prior to delivery (e.g., placen-
tal abruption, toxemia, maternal collagen vascular disease), during
delivery (e.g., prolonged labor, difficult delivery, abnormal presen-
tation), or after delivery (e.g., sepsis, shock, respiratory distress).
Currently, hypoxic-ischemic injury is diagnosed based on clinical
criteria. This review will use the term HIE although recently med-
ical experts have proposed use the term neonatal encephalopathy
instead of HIE.
A clinician’s ability to predict the outcome of neonates with
HIE is not straightforward. The Sarnat grading system (Sarnat
and Sarnat, 1976) stages HIE based on clinical criteria. This scoring
system divides neonates into mild, moderate, or severe categories,
and measures the progression of the neurologic insult to predict
a neonate’s prognosis (Finer et al., 1981). Nevertheless, the Sarnat
score system is subjective and changes over time. A new bedside
tool, amplitude integrated electroencephalogram (aEEG), may
help stage the severity of injury and predict prognosis (Hellstrom-
Westas et al., 1995). Unfortunately, the Sarnat score and aEEG
are not as effective in predicting outcomes in neonates during
hypothermia (Thoresen et al., 2010) and do not provide informa-
tion about the timing of the injury. Brain MRI can help determine
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when the injury occurred, but obtaining an MRI is not possible in
unstable patients.
Recently, therapeutic hypothermia has evolved into standard
of care for neonates with moderate to severe HIE. Prior to this
therapy, neonates were treated with systemic supportive care with
no specific therapy aimed at preventing or ameliorating ongoing
brain injury. Large randomized multicenter trials demonstrated
that hypothermia in neonates with moderate to severe HIE is safe,
improves outcomes, and has a combined number needed to treat
of one in nine (Gluckman et al., 2005; Azzopardi et al., 2009).
The next step in brain neuroprotection is the identification of bio-
markers that can facilitate clinical decisions. Biomarkers will help
clinicians identify neonates that will respond to hypothermia and
those that will need other new neuroprotective interventions. If
clinicians are able to stratify patients using biomarkers, neonates
will be protected from exposure to unnecessary, ineffective ther-
apies. Furthermore, these same infants may benefit from other
specific therapies more tailored to their biological profile. Bio-
markers will be a key feature of future neuroprotective trials and
will help gage the intervention’s short- and long-term efficacy.
BIOMARKERS OF HYPOXIC-ISCHEMIC ENCEPHALOPATHY
To date, potential biomarkers have been identified in neonates
with HIE. These biomarkers were obtained from CSF, serum, and
urine and include S100B, neuron specific enolase (NSE), umbilical
cord Interleukin-6 (IL-6), CPK-BB, glial fibrillary acidic pro-
tein (GFAP), myelin basic protein, Ubiquitin carboxyl-terminal
hydrolase L1 (UCHL-1), and pNF-H (see Table 1).
As discussed above, a primary goal of biomarkers is to iden-
tify injury and predict long-term outcomes. The best sources
for biomarkers in critically ill neonates are those fluids obtained
the least invasively. Therefore, an ideal biomarker would come
from the urine or saliva. Ideally, biomarkers could be collected
shortly after birth and help to determine the time at which the
hypoxic-ischemic injury occurred and predict the neonate’s out-
come. Counter-intuitively, biomarkers that do not originate from
brain could be good predictors of outcomes such as death and
long-term neurodevelopmental handicaps. For example, IL-6 is
an inflammatory cytokine produced by T-cells and macrophages,
and was found by Chiesa et al. (2003) to be 376-fold higher in
50 infants without infection who developed HIE compared to 113
normal infants. The IL-6 concentrations was 5.5-fold higher in the
HIE infants than the asphyxiated newborns without HIE. In addi-
tion IL-6 concentrations were significantly related to the severity
of HIE and the neurodevelopmental outcome at 2 years of age.
Maternal serum IL-6 concentration did not correlate with the risk
of neonatal HIE.
S-100 is a calcium binding protein and is a major compo-
nent of the cytosol in various cell types. In particular, glial cells
have a high concentration of S100B. S100B immunoassay kits are
commercially available and can detect S100B in many biological
fluids (urine, blood, CSF, amniotic fluid, saliva, and milk; Gazzolo
and Michetti, 2010; Gazzolo et al., 2010). Furthermore, reference
ranges are available for newborns and children through age three
(Bouvier et al., 2011) and urine S100B reference ranges for preterm
and term healthy newborns (Gazzolo et al., 2007). Serum S100B
concentrations in healthy children are higher than concentrations
reported in adults. These serum concentrations decrease over time,
especially during the first 6 months after birth. Similarly, urinary
S100B protein concentrations are higher in premature infants than
in term newborns and steadily decrease with advancing GA.
Gazzolo et al. (2004) demonstrated that S100B concentrations
in the first urine after birth were significantly higher in HIE
patients than in controls. S100B has been investigated in cord
blood samples and has been linked to HIE. Cord blood of 40
neonates with HIE had elevated S100B protein concentrations
when compared with controls (Qian et al.,2009). In the same study,
concentrations of S100B greater than 2.02µg/L had a sensitivity
of 86.7% and a specificity of 88% for predicting the development
of moderate or severe HIE.
Gazzolo et al. (2009) also demonstrated that an S100B con-
centration cut-off of 0.41 mcg/L had a sensitivity of 91.3% and
Table 1 | Summary of biomarkers characteristics.
Biomarker Description Cell specificity Pathophysiology of high plasma concentrations
BDNF Neurotrophic factor Secreted by neural progenitor stem cells,
astrocytes, and neurons. There are trace
amounts in platelets
Released after brain injury (neuronal and astrocyte
cell death) but concentration can be altered by
exercise, depression, and autoimmune disease
S100β It is a protein that binds calcium
and is a major component of the
cytosol in various cell types
Astroglial cells have a high concentration
of S100B. Other cells can release S100B
Released predominantly after astrocyte death but
can be released from other tissue damage
GFAP It is a cytoskeletal intermediate
filament protein found in the
astrocytes
Specific marker of differentiated
astrocytes
Released after astrocyte death
NSE or neuron
specific enolase
or enolase 2
Glycolytic isoenzyme (γγ) High concentrations of NSE are found in
mature central and peripheral neurons.
Although there are trace amounts of
similar isoenzyme (αγ) in platelets
Released after neuronal death
Summarizes main biomarkers for hypoxic-ischemic encephalopathy including its description, cell specificity, and pathophysiology of high plasma concentrations.
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a specificity of 94.6% for predicting the development of HIE.
The sensitivity and specificity increased to 100 and 98.8%, respec-
tively, when urine samples were collected at 4–72 h after birth. In
another study of 132 term infants, urinary S100B concentrations
were higher in infants who suffered perinatal asphyxia or died
and urine S100B above 1 mcg/L predicted neonatal death with
a sensitivity and specificity of 100%. A study by the same group
demonstrated that urinary S100B concentrations were not affected
by renal failure (Risso et al., 2011).
Glial fibrillary acidic protein is a cytoskeleton intermediate fil-
ament protein of the astrocytes and is only released into the blood
upon astrocyte death. GFAP have been correlated with poor out-
comes in adult patients after stroke, cardiac arrest, or traumatic
brain injury (Pelinka et al., 2004a). GFAP has been used as a pre-
dictor of mortality or poor neurological outcomes in children
requiring extracorporeal membrane oxygenation (Pelinka et al.,
2004b; Vos et al., 2004; Lumpkins et al., 2008; Kaneko et al., 2009;
Bembea et al., 2010). A recently published pilot study compared
23 HIE neonates who met the criteria for hypothermia with 23
NICU patients without neurologic injury (Ennen et al., 2011).
The patients with HIE had significantly elevated GFAP concentra-
tions when compared with controls. In addition, a GFAP equal to
or greater than 0.15 ng/mL upon NICU admission was predictive
of an abnormal brain MRI.
Other serum biomarkers have been explored to predict long-
term neurologic deficits after neonatal asphyxia. In a recent meta-
analysis, Ramaswamy et al. (2009) pooled data from published
studies of neonatal HIE biomarkers that followed patients beyond
12 months of age. Serum and CSF concentrations of IL-1b, IL-
6, and serum NSE were predictive of abnormal outcomes. In
addition, high GFAP concentrations in CSF were predictive of
death.
Neuron specific enolase belongs to the family of enolases,
enzymes present in all tissues and organisms capable of glycol-
ysis. Enolases have three subunits (α, β, and γ) each one encoded
by separate genes. The subunits can combine to form five different
isoenzymes: αα, αβ, αγ, ββ, and γγ. Enolase 1 (αα) is found in
liver, kidney, spleen, and adipose tissue. Enolase 3 (ββ) is muscle
specific enolase. Enolase 2 (γγ) is NSE found in central and periph-
eral neurons and neuroendocrine cells. The mature neurons and
glia can be distinguished by the content of enolase: neurons only
have NSE and glia express enolase 1 (Marangos et al., 1980a).
Minimal quantities of enolase can be found in platelets (0.045%
of the total soluble protein of platelets); nevertheless most of the
enolase found in platelets is αγ subunits (Marangos et al., 1980b).
High levels of NSE in CSF and serum are correlated with poor
outcome in patients with cardiac arrest (Roine et al., 1989; Rund-
gren et al., 2009), in patients with cerebrovascular accident (Hay
et al., 1984) and pediatric patients with traumatic brain injury
(Berger et al., 2005). Detection of NSE in peripheral serum is
only expected to occur after both, neuronal death and disruption
of the blood brain barrier. Animal models (Costine et al., 2012)
have demonstrated a correlation between the volume of cortical
injury and levels of NSE following a traumatic brain injury. Ele-
vated serum NSE concentrations in neonates undergoing cardiac
surgery correlate with poor prognosis even when parallel sam-
ples of CSF do not reveal elevated NSE levels (Schmitt et al.,
1998).
Celtik et al. (2004) explored serum neuron specific enolase as
a predictor of HIE severity. According to ROC curves, serum NSE
above 40 mcg/L obtained between 4 and 48 h could distinguish
infants with no or mild HIE from infants with moderate or severe
HIE. Additionally, serum NSE concentrations with a cut-off point
of 45.4 mcg/L could distinguish infants with poor outcomes from
infants with normal outcomes.
Analyses of brain MRIs in patients with HIE have identified the
most common patterns of brain injury: basal ganglia injury, diffuse
or focal cortical injury, and injury to watershed areas of the cortex.
Two studies have attempted to correlate biomarkers of HIE with
various MRI patterns of brain injury. Ennen et al. (2011) found
that high serum GFAP concentrations in the first 2 days of life
in neonates undergoing whole body hypothermia correlate with
abnormal brain. Douglas-Escobar et al. (2010) measured serum
UCHL-1 (found in neuronal cell bodies) and pNF-H1 (found
in white matter brain regions) in patients with severe HIE and
controls. Correlations were found between the serum levels and
the MRI patterns of injury. Both studies were pilot studies with
very low patient numbers therefore need further validation. The
ability to predict the outcomes of HIE patients may be improved
when biomarkers are used in combination with brain MRI. For
example, combining trajectory of biomarkers such as NSE with
MRI, improved the long-term prognostic prediction (Berger et al.,
2010).
A final interesting category of potential biomarkers is the neu-
rotrophins. Brain derived neurotrophic factor (BDNF) is a neu-
rotrophin that binds to the TrkB and p75NTR receptors. BDNF
supports the survival of existing neurons and encourages the
growth and differentiation of new neurons and synapses. Imam
et al. (2009) described higher cord plasma BDNF levels in new-
borns with HIE when compared with control neonates. These
elevated BDNF levels predicted poor neurologic outcomes. Our
laboratory has found evidence that brain BDNF concentrations
are increased after rodent model of neonatal HI, similar to reports
by others in the post-stroke milieu (Bejot et al., 2011). Researchers
have postulated that BDNF increases the migration of stem cells
(Borghesani et al., 2002). We can speculate from animal models,
the high plasma concentrations of BDNF are reflection of high
brain BDNF concentrations released by neural progenitor cells
and astroglia cell in an attempt to foster brain cell recovery.
FUTURE DIRECTIONS
Hypothermia is the most promising of the neuroprotective thera-
pies that have emerged over the past decade and is rapidly becom-
ing the baseline therapy upon which future neuroprotective agents
will be added. However, only one in eight neonates treated with
hypothermia respond to the treatment. Biomarkers may help the
bedside clinician identify neonates that will responders and non-
responders to hypothermia. Non-responder patients could to be
selected to add new neuroprotective strategies. Biomarkers may
help to determine the time that the injury occurred. This is impor-
tant, because hypoxic-ischemic injury often begins in utero and if
too much time has elapsed from the brain injury, neonates would
not benefit from treatment with hypothermia. This may explain
why some neonates with HIE do not respond to hypothermia. The
timing of injury also has major medico-legal ramifications for the
obstetric and neonatal team taking care of the infant.
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Table 2 | Biomarkers and their potential use in neonatal brain injury.
Biomarker Category Fluids locations Associations Usefulness
S100β Brain-specific protein Cord blood, urine,
saliva, milk blood, CSF
Pregnancy complicated with
growth restriction and trisomy 21
++
Neonates with asphyxia and HIE
Mortality in term newborns
Interleukin 6 Inflammatory maker Cord blood and blood Neonates with HIE +
GFAP Brain-specific protein CSF Neonates with HIE +
Neuron specific enolase Brain-specific protein Blood and CSF Neonates with HIE, mortality +++
Summarizes potential biomarkers of asphyxia and hypoxic-ischemic encephalopathy (HIE). These biomarkers have been detected in blood, urine, saliva, milk, cere-
brospinal fluid (CSF), and brain tissue. Usefulness of the biomarkers: (+) limited use because CSF samples are required, (++) very useful but can be altered by other
factors such as gestational age and intrauterine growth restriction, (+++) very useful because it is more specific to brain injury and detected in serum.
Using a panel of biomarkers for neonatal brain injury also
holds the promise of allowing for more individualized care of
neonates (see Table 2). For example, certain neonates may have
more of an inflammatory component than others. Once identi-
fied, these patients could be treated with agents that minimize
the inflammatory cascade. Serum levels of biomarkers could also
be utilized to monitor the neonate’s response to pharmacologic
agents. A decrease in plasma biomarker concentrations could
potentially indicate a preservation of endogenous tissue.
Biomarkers may also be able to identify specific brain regions
that undergo injury following HIE. These regions may respond
better to a specific treatment. Therefore, in the future panel
of biomarkers may be utilized to identify injury to particu-
lar brain regions. To date, none of the examined biomarker
trials have predicted the aforementioned due to small patient
numbers.
In summary, more studies are needed to correlate and validate the
clinical use of possible biomarkers of hypoxic-ischemic brain injury. In
the future, more sensitive and precise instruments for brain imaging
(such as brain MRI), brain functioning (such as NIRS, aEEG), and
long-term neuro-assessment should be incorporated to validation of
biomarkers of neonatal brain injury.
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